scholarly journals The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets

2014 ◽  
Vol 34 (6) ◽  
Author(s):  
Laura Rocchi ◽  
Stefano Caraffi ◽  
Roberto Perris ◽  
Domenica Mangieri
Keyword(s):  
Soft Tissue ◽  
Tumour Growth ◽  
Therapeutic Targets ◽  
Soft Tissue Sarcomas ◽  
Specific Target ◽  
Target Therapies ◽  
New Therapeutic Targets

Angiogenesis is important for tumour growth and metastatization. The better understanding of the mechanisms of angiogenesis in soft tissue sarcomas can lead the design of specific target therapies for this group of poorly responding tumours.

scholarly journals Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas

2019 ◽  
Vol 15 (2) ◽  
pp. e1006826 ◽  
Author(s):  
David G. P. van IJzendoorn ◽  
Karoly Szuhai ◽  
Inge H. Briaire-de Bruijn ◽  
Marie Kostine ◽  
Marieke L. Kuijjer ◽  
...  
Keyword(s):  
Gene Expression ◽  
Machine Learning ◽  
Soft Tissue ◽  
Gene Expression Data ◽  
Therapeutic Targets ◽  
Soft Tissue Sarcomas ◽  
Prognostic Biomarkers ◽  
Expression Data ◽  
Learning Analysis

scholarly journals Focus on the Tumour Periphery in MRI Evaluation of Soft Tissue Sarcoma: Infiltrative Growth Signifies Poor Prognosis

Sarcoma ◽  
2006 ◽  
Vol 2006 ◽  
pp. 1-5 ◽  
Author(s):  
Josefin Fernebro ◽  
Marie Wiklund ◽  
Kjell Jonsson ◽  
Pär-Ola Bendahl ◽  
Anders Rydholm ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Growth Pattern ◽  
Tumour Growth ◽  
Neoadjuvant Treatment ◽  
Soft Tissue Sarcomas ◽  
Prognostic Information ◽  
Diffuse Infiltration ◽  
Increased Risk ◽  
Tumour Periphery ◽  
Mri Evaluation

Purpose. Infiltrative microscopical peripheral growth of soft tissue sarcomas (STS) has been shown to be of prognostic importance and preoperative risk stratification could individualize neoadjuvant treatment.Patients and methods. We assessed peripheral tumour growth pattern on preoperative MRI from 78 STS. The findings were correlated to histopathology and to outcome.Results. The MRI-based peripheral tumour growth pattern was classified as pushing in 34 tumours, focally infiltrative in 25, and diffusely infiltrative in 19. All tumours with diffuse infiltration on MRI also showed microscopical infiltration, whereas MRI failed to identify infiltration in two-thirds of the microscopically infiltrative tumours. Diffusely infiltrative growth on MRI gave a 2.5 times increased risk of metastases (P=.01) and a 3.7 times higher risk of local recurrence (P=.02).Discussion. Based on this observation we suggest that MRI evaluation of STS should focus on the peripheral tumour growth pattern since it adds prognostic information of value for decisions on neoadjuvant therapies.

scholarly journals New Therapeutic Targets in Soft Tissue Sarcoma

2012 ◽  
Vol 19 (3) ◽  
pp. 170-180 ◽  
Author(s):  
Elizabeth G. Demicco ◽  
Robert G. Maki ◽  
Dina C. Lev ◽  
Alexander J. Lazar
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Therapeutic Targets ◽  
New Therapeutic Targets

scholarly journals Therapeutic Targets for Bone and Soft-Tissue Sarcomas

2019 ◽  
Vol 20 (1) ◽  
pp. 170 ◽  
Author(s):  
Shinji Miwa ◽  
Norio Yamamoto ◽  
Katsuhiro Hayashi ◽  
Akihiko Takeuchi ◽  
Kentaro Igarashi ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Checkpoint Inhibitors ◽  
Therapeutic Targets ◽  
Soft Tissue Sarcomas ◽  
Science Research ◽  
New Drugs ◽  
Basic Studies ◽  
Molecular Therapeutic ◽  
New Treatments ◽  
Molecular Therapeutic Targets

Due to the rarity and heterogeneity of bone and soft-tissue sarcomas, investigation into molecular targets and new treatments has been particularly challenging. Although intensive chemotherapy and establishment of surgical procedures have improved the outcomes of patients with sarcoma, the curative rate of recurrent and metastatic sarcomas is still not satisfactory. Recent basic science research has revealed some of the mechanisms of progression and metastasis of malignancies including proliferation, apoptosis, angiogenesis, tumor microenvironment, migration, invasion, and regulation of antitumor immune systems. Based on these basic studies, new anticancer drugs, including pazopanib, trabectedin, eribulin, and immune checkpoint inhibitors have been developed and the efficacies and safety of the new drugs have been assessed by clinical trials. This review summarizes new molecular therapeutic targets and advances in the treatment for bone and soft tissue sarcomas.

Sign in / Sign up

Export Citation Format

Share Document